Aktis Oncology (NASDAQ:AKTS) Reaches New 52-Week Low – Should You Sell?

Aktis Oncology (NASDAQ:AKTS) shares reached a new 52-week low on Friday . The company traded as low as $16.61 and last traded at $16.5650, with a volume of 49406 shares trading hands. The stock had previously closed at $17.62.

Wall Street Analyst Weigh In

AKTS has been the subject of a number of recent analyst reports. Leerink Partners began coverage on Aktis Oncology in a report on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 target price on the stock. Wall Street Zen upgraded Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. HC Wainwright began coverage on Aktis Oncology in a research note on Monday, March 9th. They issued a “buy” rating and a $30.00 price target for the company. Finally, TD Cowen began coverage on Aktis Oncology in a report on Tuesday, February 3rd. They set a “buy” rating on the stock. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $31.25.

Aktis Oncology Trading Down 13.8%

The company has a 50 day moving average of $19.28.

Insider Transactions at Aktis Oncology

In other news, Director Helen Susan Kim purchased 835,000 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was purchased at an average cost of $18.00 per share, with a total value of $15,030,000.00. Following the purchase, the director owned 5,671,825 shares in the company, valued at $102,092,850. This trade represents a 17.26% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm purchased 1,112,777 shares of the stock in a transaction dated Monday, January 12th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $20,029,986.00. Following the completion of the transaction, the insider owned 10,260,064 shares in the company, valued at $184,681,152. This trade represents a 12.17% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 6,117,776 shares of company stock valued at $110,119,968 over the last three months. 3.30% of the stock is owned by company insiders.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.